Results 151 to 160 of about 83,236 (262)

Tissue Resident Memory Cells: Friend or Foe?

open access: yesImmunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude   +2 more
wiley   +1 more source

Development of an immunocompetent cutaneous squamous cell carcinoma model identifies VISTA and CTLA-4 as targetable immune checkpoints. [PDF]

open access: yesJ Immunother Cancer
Rodriguez Rosario AE   +17 more
europepmc   +1 more source

Linoleic Acid Enhances Murine Natural Killer Cell Function In Vitro but Compromises Mitochondrial Bioenergetic Function During Retroviral Infection

open access: yesImmunology, EarlyView.
Natural Killer (NK) cells are potent effectors against virus‐infected and tumour cells. During Friend Virus (FV) infection, fatty acid metabolism supports NK‐cell effector functions. Here, we found that NK cells from FV‐infected mice preferentially take up linoleic acid (LA), which reduced proliferation, mitochondrial function, and increased reactive ...
Vaasudevan Sridhar   +8 more
wiley   +1 more source

Determinants of T Cell Exhaustion: How Far Back Can We Go?

open access: yesImmunology, EarlyView.
Classical versus Emerging models of CD8+ T Cell Exhaustion. Comparison of the classical ‘Endpoint Model’ (Left), where exhaustion is viewed as a terminal state requiring reversal, versus the emerging ‘Trajectory Model’ (Right). Recent studies suggest exhaustion is a continuous developmental path initiated early in infection or tumuorigenesis ...
Testimony Olumade   +2 more
wiley   +1 more source

Oral lichenoid lesions in CTLA-4 haploinsufficiency: Targeting IFN-γ-driven mucosal immunopathology. [PDF]

open access: yesJ Eur Acad Dermatol Venereol
Wang C   +11 more
europepmc   +1 more source

Five‐year survival impact of adjuvant anti‐PD‐1 therapy in a nationwide cohort of stage III melanoma

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This nationwide real‐world cohort study was unable to demonstrate a population‐level survival benefit of adjuvant anti‐PD‐1 in stage III melanoma. Matched analyses suggested higher OS in treated patients. However, limited statistical power and potential residual confounding preclude firm conclusions.
Marie B. Weitemeyer   +11 more
wiley   +1 more source

Design and Characterization of Prodrugged Anti-CTLA-4 Antibodies. [PDF]

open access: yesChembiochem
Yamazoe S   +15 more
europepmc   +1 more source

Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

open access: yesJournal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background Durvalumab plus tremelimumab (Dur/Tre) has shown promising efficacy in advanced hepatocellular carcinoma (HCC), but predictive biomarkers remain unclear. This study aimed to determine whether early changes in peripheral blood lymphocyte counts during Dur/Tre therapy can predict clinical outcomes.
Yuichi Honma   +36 more
wiley   +1 more source

Home - About - Disclaimer - Privacy